Health-Related Direct-to-Consumer Genetic Tests: A Public Health Assessment and Analysis of Practices Related to Internet-Based Tests for Risk of Thrombosis

Background: Recent years have seen increased concern about direct-to-consumer (DTC) genetic testing (i.e., the sale and use of genetic tests without involving a health care provider). Numerous professional organizations have developed policies in this area. However, little systematic evidence exists to inform public policy about these tests. Methods: We conducted a systematic search to identify genetic tests that are sold DTC without involving a health care provider. We evaluated the practices of companies offering DTC genetic tests for risk of thrombosis using criteria from multiple sources and a minimal set of key practices. Results: We identified 84 instances of currently available health-related DTC genetic tests sold on 27 Web sites; the most common were for pharmacogenomics (12), risk of thrombosis (10), and nutrigenomics (10). For the DTC genetic tests for risk of thrombosis, we found low adherence to recommendations. Online information was frequently incomplete and had low agreement with professional recommendations. Conclusion: Our findings document the rapid growth in the availability of health-related DTC genetic tests and highlight the need to improve the delivery of DTC genetic tests. A major implication of this study is the need for the scientific and medical community to develop consistent recommendations to increase their impact.

[1]  Anika Ashok,et al.  Guidance for Industry by U.S. Department of Health and Human Services—Food and Drug Administration—Center for Biologics Evaluation and Research (CBER)—February 1999 , 2009 .

[2]  M. Khoury,et al.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? , 2007, Genetics in Medicine.

[3]  Gail Javitt,et al.  ASHG Statement* on Direct-to-Consumer Genetic Testing in the United States , 2007, Obstetrics and gynecology.

[4]  B. Vastag.  US aims to tighten rules on direct-to-consumer drug ads , 2007, Nature Biotechnology.

[5]  K. Stange.  Time to Ban Direct-to-Consumer Prescription Drug Marketing , 2007, The Annals of Family Medicine.

[6]  D. Kessler,et al.  Direct-to-Consumer Advertising: Is It Too Late to Manage the Risks? , 2007, The Annals of Family Medicine.

[7]  Joan Scott,et al.  Oversight of US genetic testing laboratories , 2006, Nature Biotechnology.

[8]  A. Wolfberg,et al.  Genes on the Web--direct-to-consumer marketing of genetic testing. , 2006, The New England journal of medicine.

[9]  G. Javitt.  Pink or blue? The need for regulation is black and white. , 2006, Fertility and sterility.

[10]  S. Gilbody,et al.  Benefits and harms of direct to consumer advertising: a systematic review , 2005, Quality and Safety in Health Care.

[11]  R. Clarke,et al.  Homocysteine, MTHFR and risk of venous thrombosis: a meta‐analysis of published epidemiological studies , 2005, Journal of thrombosis and haemostasis : JTH.

[12]  E. McCabe,et al.  Direct-to-consumer genetic testing: Access and marketing , 2004, Genetics in Medicine.

[13]  Olufunmilayo I Olopade,et al.  Direct-to-consumer marketing of genetic tests for cancer: buyer beware. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Wilfond,et al.  Direct-to-consumer sales of genetic services on the Internet , 2003, Genetics in Medicine.

[15]  Ira M Lubin,et al.  Physicians’ perceived usefulness of and satisfaction with test reports for cystic fibrosis (ΔF508) and factor V Leiden , 2003, Genetics in Medicine.

[16]  N. Key,et al.  Role of the geneticist in testing and counseling for inherited thrombophilia , 2003, Genetics in Medicine.

[17]  J. Heit,et al.  Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. , 2002, Archives of pathology & laboratory medicine.

[18]  J. Rice,et al.  Medical genetic test reporting for cystic fibrosis (ΔF508) and factor V Leiden in North American laboratories , 2002, Genetics in Medicine.

[19]  W. Grody,et al.  American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing , 2001, Genetics in Medicine.

[20]  S. Hull,et al.  Reading between the lines: Direct-to-consumer advertising of genetic testing in the USA , 2001, Reproductive health matters.

[21]  Dietary Supplements: An Advertising Guide for Industry , 2001, Critical reviews in food science and nutrition.

[22]  Gregg Pratt,et al.  DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 1998 .

[23]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[24]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[25]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[26]  W. Raub.  From the National Institutes of Health. , 1990, JAMA.